Is SURG or PSTV more profitable?

SurgePays has a net margin of -64.91% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat SurgePays' return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% -967.32% -310.16% Plus Therapeutics -230.24% -198.48% -73.13%

Is SURG or NSPR more profitable?

SurgePays has a net margin of -64.91% compared to InspireMD's net margin of -413.96%. InspireMD's return on equity of -69.42% beat SurgePays' return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% -967.32% -310.16% InspireMD -413.96% -69.42% -57.68%

Does the media prefer SURG or NSPR?

In the previous week, InspireMD had 2 more articles in the media than SurgePays. MarketBeat recorded 4 mentions for InspireMD and 2 mentions for SurgePays. SurgePays' average media sentiment score of 0.77 beat InspireMD's score of 0.72 indicating that SurgePays is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SurgePays 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive InspireMD 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SURG or NTRB?

SurgePays currently has a consensus target price of $5.00, indicating a potential upside of 851.29%. Given SurgePays' stronger consensus rating and higher probable upside, equities analysts plainly believe SurgePays is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SurgePays 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is SURG or NTRB more profitable?

SurgePays has a net margin of -64.91% compared to Nutriband's net margin of -403.98%. Nutriband's return on equity of -118.33% beat SurgePays' return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% -967.32% -310.16% Nutriband -403.98% -118.33% -101.92%

Which has higher valuation & earnings, SURG or STRR?

Star Equity has higher revenue and earnings than SurgePays. Star Equity is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SurgePays $56.96M 0.23 -$36.07M -$1.94 N/A Star Equity $172.16M 0.25 -$5.92M -$2.63 N/A

Is SURG or STRR more profitable?

Star Equity has a net margin of -4.18% compared to SurgePays' net margin of -64.91%. Star Equity's return on equity of -4.04% beat SurgePays' return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% -967.32% -310.16% Star Equity -4.18% -4.04% -2.40%

Does the media favor SURG or STRR?

In the previous week, Star Equity had 10 more articles in the media than SurgePays. MarketBeat recorded 12 mentions for Star Equity and 2 mentions for SurgePays. Star Equity's average media sentiment score of 1.24 beat SurgePays' score of 0.77 indicating that Star Equity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SurgePays 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Star Equity 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, SURG or TELA?

SurgePays has higher earnings, but lower revenue than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SurgePays $56.96M 0.23 -$36.07M -$1.94 N/A TELA Bio $80.28M 0.48 -$38.83M -$0.79 N/A

Is SURG or TELA more profitable?

TELA Bio has a net margin of -49.30% compared to SurgePays' net margin of -64.91%. SurgePays' return on equity of -967.32% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% -967.32% -310.16% TELA Bio -49.30% -1,320.81% -55.83%

SurgePays (SURG) Competitors

$0.53 -0.03 (-5.57%)

Closing price 04:00 PM Eastern

Extended Trading

$0.54 +0.02 (+3.31%)

As of 07:38 PM Eastern

Compare

SURG vs. PSTV, NSPR, NTRB, STRR, and TELA

Should you buy SurgePays stock or one of its competitors? MarketBeat compares SurgePays with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SurgePays include Plus Therapeutics (PSTV), InspireMD (NSPR), Nutriband (NTRB), Star Equity (STRR), and TELA Bio (TELA). These companies are all part of the "medical equipment" industry.

How does SurgePays compare to Plus Therapeutics?

SurgePays (NASDAQ:SURG) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

In the previous week, SurgePays had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 2 mentions for SurgePays and 1 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 1.89 beat SurgePays' score of 0.77 indicating that Plus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
SurgePays	Positive
Plus Therapeutics	Very Positive

SurgePays currently has a consensus price target of $5.00, suggesting a potential upside of 851.29%. Plus Therapeutics has a consensus price target of $58.00, suggesting a potential upside of 970.11%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Plus Therapeutics is more favorable than SurgePays.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Plus Therapeutics has lower revenue, but higher earnings than SurgePays. Plus Therapeutics is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.23	-$36.07M	-$1.94	N/A
Plus Therapeutics	$5.21M	7.16	-$22.39M	-$2.30	N/A

6.9% of SurgePays shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 29.1% of SurgePays shares are held by insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

SurgePays has a net margin of -64.91% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	-967.32%	-310.16%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

SurgePays has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

Summary

Plus Therapeutics beats SurgePays on 9 of the 16 factors compared between the two stocks.

How does SurgePays compare to InspireMD?

SurgePays (NASDAQ:SURG) and InspireMD (NYSE:NSPR) are both small-cap medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

In the previous week, InspireMD had 2 more articles in the media than SurgePays. MarketBeat recorded 4 mentions for InspireMD and 2 mentions for SurgePays. SurgePays' average media sentiment score of 0.77 beat InspireMD's score of 0.72 indicating that SurgePays is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SurgePays	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
InspireMD	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SurgePays presently has a consensus target price of $5.00, suggesting a potential upside of 851.29%. InspireMD has a consensus target price of $4.50, suggesting a potential upside of 368.70%. Given SurgePays' higher possible upside, analysts clearly believe SurgePays is more favorable than InspireMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

6.9% of SurgePays shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 29.1% of SurgePays shares are owned by company insiders. Comparatively, 29.7% of InspireMD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

InspireMD has lower revenue, but higher earnings than SurgePays. InspireMD is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.23	-$36.07M	-$1.94	N/A
InspireMD	$10.85M	4.15	-$19.92M	-$0.73	N/A

SurgePays has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, InspireMD has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

SurgePays has a net margin of -64.91% compared to InspireMD's net margin of -413.96%. InspireMD's return on equity of -69.42% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	-967.32%	-310.16%
InspireMD	-413.96%	-69.42%	-57.68%

Summary

InspireMD beats SurgePays on 11 of the 16 factors compared between the two stocks.

How does SurgePays compare to Nutriband?

SurgePays (NASDAQ:SURG) and Nutriband (NASDAQ:NTRB) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Nutriband has lower revenue, but higher earnings than SurgePays. Nutriband is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.23	-$36.07M	-$1.94	N/A
Nutriband	$2.04M	20.60	-$8.23M	-$2.60	N/A

SurgePays has a net margin of -64.91% compared to Nutriband's net margin of -403.98%. Nutriband's return on equity of -118.33% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	-967.32%	-310.16%
Nutriband	-403.98%	-118.33%	-101.92%

6.9% of SurgePays shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 29.1% of SurgePays shares are held by insiders. Comparatively, 52.2% of Nutriband shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, SurgePays had 1 more articles in the media than Nutriband. MarketBeat recorded 2 mentions for SurgePays and 1 mentions for Nutriband. Nutriband's average media sentiment score of 0.93 beat SurgePays' score of 0.77 indicating that Nutriband is being referred to more favorably in the news media.

Company	Overall Sentiment
SurgePays	Positive
Nutriband	Positive

SurgePays currently has a consensus target price of $5.00, indicating a potential upside of 851.29%. Given SurgePays' stronger consensus rating and higher probable upside, equities analysts plainly believe SurgePays is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

SurgePays has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Nutriband has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

Summary

SurgePays and Nutriband tied by winning 8 of the 16 factors compared between the two stocks.

How does SurgePays compare to Star Equity?

SurgePays (NASDAQ:SURG) and Star Equity (NASDAQ:STRR) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Star Equity has higher revenue and earnings than SurgePays. Star Equity is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.23	-$36.07M	-$1.94	N/A
Star Equity	$172.16M	0.25	-$5.92M	-$2.63	N/A

SurgePays currently has a consensus target price of $5.00, indicating a potential upside of 851.29%. Star Equity has a consensus target price of $28.00, indicating a potential upside of 142.42%. Given SurgePays' higher probable upside, research analysts plainly believe SurgePays is more favorable than Star Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Star Equity	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

SurgePays has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Star Equity has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

6.9% of SurgePays shares are held by institutional investors. Comparatively, 3.8% of Star Equity shares are held by institutional investors. 29.1% of SurgePays shares are held by company insiders. Comparatively, 33.5% of Star Equity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Star Equity has a net margin of -4.18% compared to SurgePays' net margin of -64.91%. Star Equity's return on equity of -4.04% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	-967.32%	-310.16%
Star Equity	-4.18%	-4.04%	-2.40%

In the previous week, Star Equity had 10 more articles in the media than SurgePays. MarketBeat recorded 12 mentions for Star Equity and 2 mentions for SurgePays. Star Equity's average media sentiment score of 1.24 beat SurgePays' score of 0.77 indicating that Star Equity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SurgePays	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Star Equity	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Star Equity beats SurgePays on 12 of the 16 factors compared between the two stocks.

How does SurgePays compare to TELA Bio?

SurgePays (NASDAQ:SURG) and TELA Bio (NASDAQ:TELA) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

SurgePays has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, TELA Bio has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

TELA Bio has a net margin of -49.30% compared to SurgePays' net margin of -64.91%. SurgePays' return on equity of -967.32% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	-967.32%	-310.16%
TELA Bio	-49.30%	-1,320.81%	-55.83%

In the previous week, SurgePays and SurgePays both had 2 articles in the media. TELA Bio's average media sentiment score of 0.94 beat SurgePays' score of 0.77 indicating that TELA Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
SurgePays	Positive
TELA Bio	Positive

6.9% of SurgePays shares are held by institutional investors. Comparatively, 94.4% of TELA Bio shares are held by institutional investors. 29.1% of SurgePays shares are held by company insiders. Comparatively, 4.7% of TELA Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

SurgePays has higher earnings, but lower revenue than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.23	-$36.07M	-$1.94	N/A
TELA Bio	$80.28M	0.48	-$38.83M	-$0.79	N/A

SurgePays presently has a consensus target price of $5.00, indicating a potential upside of 851.29%. TELA Bio has a consensus target price of $2.20, indicating a potential upside of 155.81%. Given SurgePays' higher possible upside, analysts clearly believe SurgePays is more favorable than TELA Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

TELA Bio beats SurgePays on 10 of the 15 factors compared between the two stocks.

Get SurgePays News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SURG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SURG vs. The Competition

Export

Metric	SurgePays	INTERNET SOFTWARE Industry	Computer Sector	NASDAQ Exchange
Market Cap	$13.98M	$18.00B	$41.29B	$12.54B
Dividend Yield	N/A	2.91%	3.06%	5.22%
P/E Ratio	-0.27	63.44	173.02	24.18
Price / Sales	0.23	44.71	622.02	112.26
Price / Cash	N/A	80.60	53.03	57.13
Price / Book	-0.80	6.48	10.09	6.72
Net Income	-$36.07M	$386.39M	$1.06B	$337.19M
7 Day Performance	-4.61%	4.03%	3.81%	0.48%
1 Month Performance	-8.05%	6.08%	10.98%	5.07%
1 Year Performance	-82.12%	-3.45%	170.16%	34.25%

SurgePays Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SURG SurgePays	3.0757 of 5 stars	$0.53 -5.6%	$5.00 +851.3%	-81.3%	$13.98M	$56.96M	N/A	40	Short Interest Decrease
PSTV Plus Therapeutics	3.0118 of 5 stars	$6.81 +3.3%	$58.00 +751.7%	-40.5%	$46.85M	$5.21M	N/A	20	Positive News
NSPR InspireMD	4.1128 of 5 stars	$0.93 -7.2%	$4.50 +385.1%	-60.2%	$43.45M	$10.85M	N/A	50
NTRB Nutriband	0.6909 of 5 stars	$3.55 -2.5%	N/A	-56.2%	$43.17M	$2.04M	N/A	10	Gap Down
STRR Star Equity	4.3286 of 5 stars	$11.32 -1.4%	$28.00 +147.3%	+334.1%	$41.88M	$172.16M	N/A	1,200	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SURG) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SurgePays (SURG) Competitors

SURG vs. PSTV, NSPR, NTRB, STRR, and TELA

How does SurgePays compare to Plus Therapeutics?

Summary

How does SurgePays compare to InspireMD?

Summary

How does SurgePays compare to Nutriband?

Summary

How does SurgePays compare to Star Equity?

Summary

How does SurgePays compare to TELA Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SURG vs. The Competition

SurgePays Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SurgePays (SURG) Competitors

SURG vs. PSTV, NSPR, NTRB, STRR, and TELA

How does SurgePays compare to Plus Therapeutics?

Does the media favor SURG or PSTV?

Do analysts recommend SURG or PSTV?

Which has higher earnings & valuation, SURG or PSTV?

Do institutionals & insiders hold more shares of SURG or PSTV?

Is SURG or PSTV more profitable?

Which has more risk and volatility, SURG or PSTV?

Summary

How does SurgePays compare to InspireMD?

Does the media prefer SURG or NSPR?

Do analysts prefer SURG or NSPR?

Do institutionals and insiders hold more shares of SURG or NSPR?

Which has higher valuation and earnings, SURG or NSPR?

Which has more volatility & risk, SURG or NSPR?

Is SURG or NSPR more profitable?

Summary

How does SurgePays compare to Nutriband?

Which has preferable valuation & earnings, SURG or NTRB?

Is SURG or NTRB more profitable?

Do insiders and institutionals have more ownership in SURG or NTRB?

Does the media prefer SURG or NTRB?

Do analysts rate SURG or NTRB?

Which has more risk and volatility, SURG or NTRB?

Summary

How does SurgePays compare to Star Equity?

Which has higher valuation & earnings, SURG or STRR?

Do analysts rate SURG or STRR?

Which has more risk and volatility, SURG or STRR?

Do insiders and institutionals have more ownership in SURG or STRR?

Is SURG or STRR more profitable?

Does the media favor SURG or STRR?

Summary

How does SurgePays compare to TELA Bio?

Which has more volatility and risk, SURG or TELA?

Is SURG or TELA more profitable?

Does the media favor SURG or TELA?

Do insiders and institutionals believe in SURG or TELA?

Which has preferable valuation & earnings, SURG or TELA?

Do analysts prefer SURG or TELA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SURG vs. The Competition

SurgePays Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools